Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031957 | 1.00 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL29367495 | 1.00 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CA1 | |
| Hydrochloric Acid SCHEMBL1595146 | 0.98 | KMT2A (0.65) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL27640993 | 0.88 | KMT2A (0.57) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL21332462 | 0.86 | KMT2A (0.66) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL18510206 | 0.85 | KMT2A (0.61) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL30238049 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL1800381 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL25612527 | 0.84 | KMT2A (0.68) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL1105520 | 0.84 | KMT2A (0.63) | KMT2AEPHX2FABP5FABP7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 700 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| CN-117457312-A | Magnetic molecular probe for specifically capturing metabolites from complex sample, and preparation method and application thereof | 中国医学科学院基础医学研究所 | 2024-01-26 | — | — | CN | claimed |
| EP-4286393-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-12-06 | — | — | EP | claimed |
| US-11796534-B2 | Methods for assessing cell surface glycosylation | JUNO THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | claimed |
| WO-2022163846-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | 第一三共株式会社 | 2022-08-04 | — | — | WO | claimed |
| WO-2022015162-A1 | QUANTITATIVE DETECTION OF REDUCING SUGARS | DUCARES B.V. (NL) | 2022-01-20 | — | — | WO | claimed |
| US-20210255173-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | JUNO THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | claimed |
| EP-3610261-A1 | METHODS FOR ASSESSING CELL SURFACE GLYCOSYLATION | Juno Therapeutics, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| CN-110709700-A | Method for evaluating cell surface glycosylation | 朱诺治疗学股份有限公司 | 2020-01-17 | — | — | CN | claimed |
| EP-2691452-B1 | CURABLE FLUOROELASTOMER COMPOSITION | DU PONT (US) | 2018-11-28 | — | — | EP | claimed |
| WO-2009150834-A1 | METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN | 住友ベークライト株式会社 (JP) | 2009-12-17 | — | — | WO | claimed |
| US-20090306291-A1 | SUGAR CHAIN-CAPTURING SUBSTANCE AND USE THEREOF | SUMITOMO BAKELITE CO., LTD. (JP) | 2009-12-10 | — | — | US | claimed |
| CN-101501492-A | Sugar chain-capturing substance and use thereof | SUMITOMO BAKELITE CO (JP) | 2009-08-05 | — | — | CN | claimed |
| EP-2056106-A1 | SUGAR CHAIN-CAPTURING SUBSTANCE AND USE THEREOF | Sumitomo Bakelite Company, Ltd. (JP) | 2009-05-06 | — | — | EP | claimed |
| US-20090023590-A1 | Trichloro Silyl Alkyl Isocyanate Molecule and Surface Modified Mineral Substrate | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-01-22 | — | — | US | claimed |
| WO-2008130924-A2 | ISOTOPICALLY-LABELED GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| EP-1817425-A1 | TRICHLORO SILYL ALKYL ISOCYANATE MOLECULE AND SURFACE MODIFIED MINERAL SUBSTRATE | Centre National de la Recherche Scientifique (FR) | 2007-08-15 | — | — | EP | claimed |
| WO-2006056490-A1 | TRICHLORO SILYL ALKYL ISOCYANATE MOLECULE AND SURFACE MODIFIED MINERAL SUBSTRATE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-06-01 | — | — | WO | claimed |
| WO-2002094769-A1 | SOLID REAGENT FOR SAMPLING AND DERIVATIZATION OF CARBONYL COMPOUNDS | SEQUANT AB (SE) | 2002-11-28 | — | — | WO | claimed |
| WO-1992009568-A1 | FLUORESCENCE LABELLING REAGENT AND USE THEREFOR | MONASH UNIVERSITY (AU) | 1992-06-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | KMT2A 3598/4885EPHX2 1105/4885FABP5 4379/4885 |
| US-20090023590-A1 | Trichloro Silyl Alkyl Isocyanate Molecule and Surface Modified Mineral Substrate | TST, MSMO1, ESPL1 | KMT2A 3599/4885EPHX2 2322/4885FABP5 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.